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database from a US national commercially-insured population (January 1, 2003-Sep-
tember 30, 2008). Women aged ≥18 were selected with ≥2 BC diagnoses on different 
dates within 90 days. The date of the ﬁrst BC diagnosis was the index date for case 
cohort. The control cohort (without BC diagnosis) was selected with a 3:1 ratio by 
matching to the cases based on index date (same year and month), age (5-year range), 
region, employer, and health insurance type. Both cohorts were required to have 
continuous enrollment for at least 6-months prior to and 12-months after the index 
date. Generalized linear model (GLM) was applied to evaluate the 1-year post-index 
cost difference between cases and controls with adjustment of demographics, comor-
bid conditions, and pre-index total health care cost. RESULTS: Based on the selection 
criteria, 140,228 patients were included with mean (SD) age of 52.1 (7.5) years. The 
total 1-year health care costs for cases and controls were $61,167 and $6,296, respec-
tively (p < 0.001). GLM predicted that the adjusted incremental health care cost was 
$42,401 (p < 0.001) per BC patient per year, which included 12%, 86%, and 2% for 
inpatient, outpatient, and prescription use. CONCLUSIONS: This study demonstrated 
that breast cancer is an expensive disease condition, which consumes on average 
$40,000 more per patient within the ﬁrst year of diagnosis for the US health care 
system. Most of the direct health care cost is spent in outpatient care settings.
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OBJECTIVES: Few data exist on the impact of breast cancer (BC) on absenteeism and 
short-term disability (STD) to employers. This study was undertaken to estimate BC 
related indirect cost impacts within the US population. METHODS: This was a ret-
rospective matched cohort study using a large health care claims database from a US 
national commercially-insured population (2003–2007). Women aged ≥18 were 
selected with ≥2 BC diagnoses on different dates within 90 days. The date of the ﬁrst 
BC diagnosis was the index date for case cohort. The control cohort (without BC 
diagnosis) was selected with 1:1 matching to cases based on index date (same year 
and month), age (5 year range), region, employer, and health insurance type. Continu-
ous enrollment for at least 6-months prior to and 12-months after the index date was 
required for both cohorts. Indirect cost was measured by days of absenteeism and 
STD, multiplied by age-matched average wage rates from Bureau of Labor Statistics. 
Two-part model was used to assess the 1-year post-index indirect cost difference 
between cases and controls with the adjustment of demographics, comorbid condi-
tions, and pre-index total health care cost. RESULTS: Based on the inclusion criteria, 
856 and 2668 patients were selected for absenteeism and STD outcomes, respectively. 
Costs of absenteeism were $4972 and $2937, and costs of STD were $7199 and $653 
for cases and controls, respectively, within the post-index year (both p < 0.001). Two-
part models predicted that the adjusted incremental costs for absenteeism and STD 
were $1911 and $6157 (p < 0.001) per BC patient per year. CONCLUSIONS: This 
study demonstrated that breast cancer is associated with approximately $8000 more 
in indirect cost per patient to the employer within the ﬁrst year of diagnosis.
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OBJECTIVES: Little is known about how resource utilization in the initial treatment 
period among advanced stage PCa patients differs between those receiving versus those 
not receiving chemotherapy, even for docetaxel, the earliest approved agent for meta-
static disease. METHODS: We analyzed patients aged 66 or older from the linked 
Surveillance, Epidemiology, and End Results & Medicare (SEER-Medicare) database. 
Patients were diagnosed with PCa between 2000 and 2005 and were followed until 
censoring. We restricted the cohort to patients with incident Stage IV disease (AJCC-
TNM classiﬁcation) and at least 24 months of post-diagnosis follow-up data. Initial 
costs (Medicare payments) were deﬁned as costs incurred from 2 months before 
diagnosis to 12 months post-diagnosis and patients were stratiﬁed according to whether 
they received chemotherapy, and subsequently, whether they received docetaxel. 
RESULTS: Application of the inclusion criteria resulted in 4,088 Stage IV PCa patients, 
of which 23% (N = 933) reported chemotherapy. Among chemotherapy users, 63% 
(N = 592) received docetaxel-containing regimens. Initial costs totaled $78.3M while 
PCa-speciﬁc initial costs totaled $49.9M. For the full sample (F), chemotherapy 
subsample (C), and no chemotherapy subsample (NC), the proportions of total costs 
attributed to PCa-speciﬁc inpatient costs (IC), non-PCa-speciﬁc IC, PCa-speciﬁc out-
patient costs (OC), non-PCa-speciﬁc OC, and other costs were distributed as follows: 
1) PCa-speciﬁc IC: F = 26.5% [$20.7M]; C = 23.4% [$4.7M]; NC = 27.5% [$16.0M] 
2) non-PCa-speciﬁc IC: F = 12.3% [$9.7M]; C = 10.3% [$2.1M]; NC = 13.1% [$7.6M] 
3) PCa-speciﬁc OC: F = 35.9% [$28.1M]; C = 42.1% [$8.5M]; NC = 33.8% [$19.6M] 
4) non-PCa-speciﬁc OC: F = 20.8% [$16.3M]; C = 22.5% [$4.5M]; NC = 20.1% 
[$11.7M] and 5) Other costs: F = 4.5% [$3.5M]; C = 1.7% [$0.3]; NC = 5.5% 
[$3.2M]. The proportion of PCa-speciﬁc outpatient costs was higher in the docetaxel 
subsample compared to the chemotherapy subsample. CONCLUSIONS: Among 
patients diagnosed with advanced disease, PCa-speciﬁc inpatient and outpatient costs 
accounted for two-thirds of Medicare payments, with PCa-speciﬁc outpatient costs 
gaining larger shares in the chemotherapy and docetaxel subsamples.
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OBJECTIVES: Metastatic Melanoma (MM) is associated with serious clinical and 
humanistic burden. This study calculated the cost and medical resource utilization 
attributable to MM in a large geographically diverse commercially insured US popula-
tion. METHODS: The MEDSTAT MarketScan® database (1/1/2000–12/31/2008) 
identiﬁed patients aged ≥18 years with ≥2 melanoma claims (ICD-9-CM 172.xx, 
V10.82), or ≥1 melanoma claim and ≥1 chemotherapies. After excluding patients with 
other malignant tumors and those with <1 month post-index or <6 months of pre-
index, 2 mutually exclusive cohorts were formed. Patients with diagnosis of metastasis 
or related chemotherapies were categorized as MM, and the remaining as non-MM. 
Index-date was the ﬁrst date of diagnosis of melanoma or MM respectively. Mean 
estimates of per-patient-per-month (PPPM) resource utilization and cost (in 2008 
dollars) within each group (pre vs. post) were statistically compared. Attributed cost 
of metastasis was the difference in mean differences (post-pre) between the groups. 
RESULTS: The study identiﬁed 407 MM and 13,796 non-MM patients (mean age 
48.8 and 47.8 years, respectively). For the MM patients, PPPM utilization increased 
3 to 12 times from the pre-metastatic period (inpatient: 0.007 to 0.090, emergency 
room: 0.010 to 0.044, ofﬁce: 0.724 to 2.592, all with p < 0.0001, and hospital out-
patient: 0.226 to 1.029, p = 0.0442), while the PPPM total cost increased 7 times 
($803.2 to $5,439.9, p < 0.0001). For the non-MM patients, utilization increased 
marginally following melanoma diagnosis (inpatient: 0.005 to 0.008, emergency 
room: 0.012 to 0.016, ofﬁce: 0.696 to 1.214, and hospital outpatient: 0.136 to 0.291, 
all p < 0.0001). The total cost for non-MM patients doubled following diagnosis of 
melanoma ($432.3 to $955.2, p < 0.0001). Upon metastasis, the disease attributed 
cost increased 9 times ($523 to $4638). CONCLUSIONS: The cost burden from 
resource utilization increases substantially with metastasis of melanoma. Treatments 
that signiﬁcantly delay disease progression in these patients will reduce this burden.
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OBJECTIVES: To estimate the health care costs, treatment patterns, and health care 
resource use in advanced ovarian cancer (aOC) patients receiving ﬁrst line chemo-
therapy. METHODS: Incident aOC patients between 2000–2005 were identiﬁed from 
the linked Surveillance, Epidemiology and End-Results (SEER)/Medicare data ﬁle using 
an ICD-9 code 56.9 with a “distant” tumor in the SEER staging variable. Women ≥65 
years at the time of aOC diagnosis (i.e. index date), with at least three months of data 
preceding the initial diagnosis were included. Subjects were followed from 30 days 
prior to index date until the ﬁrst occurrence of the following: receipt of a 2nd line treat-
ment given after a minimum of 90 days treatment free interval, death or the end of the 
Medicare claims data (i.e., December 2007). Measures of overall HRU included hospi-
talizations, outpatient visits, physician visits, hospice care, home health care, and 
skilled nursing facility utilization. Costs of each HRU event were estimated by summing 
all Medicare payments, primary insurer payments, patient copayments and deductibles 
for services in the claims ﬁles. Average health care costs per event per patient (e.g. 
hospitalization) are calculated as total cost per event divided by number of patients with 
the event. RESULTS: A total of 3895 aOC subjects receiving ﬁrst-line chemotherapy 
were included in the analysis. Mean age was 75 years. Carboplatin+paclitaxel (73%), 
carboplatin alone (8.5%), and carboplatin+docetaxel (7%) were the three most com-
monly used 1st line chemotherapeutic agents. The mean 1st line treatment duration was 
128 days (SD 95.8). The rate of hospitalization was 1.5 per person-year. Mean hospi-
talization cost per patient was $12,997 (SD $10,499). Mean SNF and Hospice Care 
costs per patient were $7,509 (SD $7,171) and $7,025 (SD $11,370) respectively. 
CONCLUSIONS: Carboplatin-paclitxel combination was the most commonly used 
ﬁrst line chemotherapeutic regimen. In aOC patients, hospitalization costs were sub-
stantial in women with aOC receiving 1st line chemotherapy.
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OBJECTIVES: To evaluate insurer and patient cost increases during the ﬁrst year 
following hepatocellular carcinoma (HCC) diagnosis. METHODS: Subjects in the 
Medstat MarketScan® claims database (July 1, 2005–June 30, 2008) were included 
for analysis if they were age ≥18 years, had ≥1 HCC claim (ICD9 155.0) from July 
1, 2006 to June 30, 2007, no cancer claims in the year prior to the ﬁrst HCC claim 
(index), and a full year of pre-index data. Per patient per month (PPPM) cost estimates 
were compared pre- and post- diagnosis with a sign rank test. RESULTS: The analyti-
cal dataset included 440 patients: mean age 53 years, 61% male, mean follow-up 256 
